Download Files:
Fenebrutinib
$66 – $1,265
Products Details
Product Description
– Fenebrutinib (GDC-0853) is a potent, selective, orally available, and noncovalent bruton’s tyrosine kinase (Btk) inhibitor with Kis of 0.91 nM, 1.6, 1.3, 12.6, and 3.4 nM for WT Btk, and the C481S, C481R, T474I, T474M mutants. Fenebrutinib has the potential for rheumatoid arthritis and systemic lupus erythematosus research[1].
Web ID
– HY-19834
Storage Temperature
– 4°C (Powder, stored under nitrogen)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C37H44N8O4
References
– [1]Crawford JJ, et al. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development. J Med Chem. 2018 Mar 22;61(6):2227-2245.|[2]Erickson RI , et al. Bruton’s Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats. J Pharmacol Exp Ther. 2017 Jan;360(1):226-238.
CAS Number
– 1434048-34-6
Molecular Weight
– 664.80
Compound Purity
– 99.42
SMILES
– O=C1C(NC(C=C2)=NC=C2N3CCN(C4COC4)C[C@@H]3C)=CC(C5=CC=NC(N6C(C7=CC(CC(C)(C)C8)=C8N7CC6)=O)=C5CO)=CN1C
Clinical Information
– Phase 3
Research Area
– Cancer
Solubility
– DMSO : ≥ 23 mg/mL
Target
– Btk
Pathway
– Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
